Reaction
Diffuse Large B-Cell Lymphoma Stage Iv reporting signals
As of the last recalculation, Diffuse Large B-Cell Lymphoma Stage Iv appears in 319 FAERS reports alongside 18 co-occurring drug terms. The strongest observed disproportionality signal is POLATUZUMAB VEDOTIN (PRR 189.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Polatuzumab Vedotin | 26 | 189.2 | 189.7 |
| Axicabtagene Ciloleucel | 12 | 82.4 | 82.5 |
| Ifosfamide | 24 | 78.7 | 78.8 |
| Doxorubicin | 67 | 61.8 | 61.9 |
| Bendamustine Hcl | 12 | 52.4 | 52.5 |
| Cyclophosphamide Injection, Solution | 94 | 48.7 | 48.7 |
| Cyclophosphamide | 94 | 48.7 | 48.7 |
| Cyclophosphamide For Injection | 94 | 48.7 | 48.7 |
| Cytarabine | 37 | 45.3 | 45.3 |
| Fludarabine Phosphate | 24 | 43.0 | 43.0 |
| Dutasteride | 5 | 40.7 | 40.8 |
| Selinexor | 5 | 38.3 | 38.3 |
| Etoposide | 35 | 34.8 | 34.8 |
| Mesna Injection | 4 | 32.0 | 32.0 |
| Mesna | 4 | 31.4 | 31.4 |
| Baricitinib | 4 | 27.4 | 27.4 |
| Brentuximab Vedotin | 4 | 25.8 | 25.8 |
| Obinutuzumab | 5 | 20.1 | 20.1 |